"Pembrolizumab-induced thyroid storm" by Ewelina Niedzialkowska, Lark Steafo et al.
 

Pembrolizumab-induced thyroid storm

Document Type

Article

Publication Date

2025

Publication Title

Proceedings (Baylor University. Medical Center)

Abstract

Immune checkpoint inhibitors (ICIs) are novel treatment modalities that have revolutionized the field of oncology. Their widespread use in various cancers and prolonged survival of patients led to the identification of a wide range of side effects associated with the therapy, known as immune-related adverse effects (irAEs). IrAEs are presumed to arise from immunologic enhancement and frequently result in endocrine disorders. Thyroid dysfunction is not uncommon during therapy with pembrolizumab and affects up to 13% to 14% of patients. Thyroid storm associated with ICIs is extremely rare. We present a case of a 34-year-old woman with metastatic ovarian carcinoma who developed thyroid storm shortly after an addition of pembrolizumab.

Volume

38

Issue

2

First Page

199

Last Page

201

DOI

10.1080/08998280.2024.2413320

ISSN

0899-8280

PubMed ID

39989990

Share

COinS